Physician profile
Pooja Khator
NPI 1376592741
$8,547.75
in general payments reported to CMS, 2019-2025
23 companies · $1,881 in 2025
The $1,881 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $813 · 2020: $1,085 · 2021: $595 · 2022: $1,283 · 2023: $1,811 · 2024: $1,079 · 2025: $1,881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,771.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,429.23 | 2019-2025 | Clareon, Hydrus Microstent, Rocklatan |
| Abbvie INC. | $1,812.25 | 2022-2025 | |
| Allergan, INC. | $1,275.41 | 2019-2022 | |
| Sight Sciences, INC. | $794.05 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Glaukos Corporation | $461.10 | 2019-2025 | Idosetr, Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Sun Pharmaceutical Industries INC. | $189.93 | 2021-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $188.70 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $188.36 | 2021-2025 | Tecnis Iol |
| Bausch & Lomb Americas INC. | $177.56 | 2022-2025 | Vyzulta, Miebo |
| Harrow Eye, LLC | $175.88 | 2024-2025 | Vevye |
| Ocular Therapeutix, INC. | $171.27 | 2019-2025 | Dextenza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $147.24 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $137.84 | 2025 | Acuvue |
| Horizon Therapeutics Plc | $125.00 | 2023 | Tepezza |
| Coopervision INC. | $43.12 | 2025 | Clariti Contact Lens |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dutch Ophthalmic, USA | $42.34 | 2024 | Eva, Combined Machine, Tissueblue |
| Shire North American Group INC | $40.63 | 2019 | |
| New World Medical,INC. | $38.80 | 2023-2024 | Streamline, Kahook Dual Blade, Clearpath |
| Novartis Pharmaceuticals Corporation | $36.25 | 2022-2023 | |
| Thea Pharma INC. | $29.79 | 2024 | Iyuzeh |
| Amgen INC. | $25.59 | 2025 | Tepezza |
| Rayner Intraocular Lenses Limited | $17.41 | 2024 | Rayone Spheric, Omidria, Rayone Aspheric |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$165,054.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pooja Khator listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.